Why Wesfarmers shares remain the gold standard of ASX retail investing
Wesfarmers (ASX: WES) shares have fallen 9% over 12 months despite the ASX 200 rising 7%, after the stock traded at 37x forward earnings in mid-2025. For the half-year ended Dec 2025, NPAT rose 9.3% to $1,603m and free cash flow rose 35.6% to $2,745m. Morgans upgraded to accumulate, lifting its $81.10 target, citing valuation at ~28.5x earnings.
How this was made
The 30-second read
Why it matters
It links near-term support to half-year earnings/free cash flow growth and dividend lift, while positioning lithium as a developing earnings driver that could expand upside beyond retail.
Market read
A valuation reset plus improving cash generation and a broker upgrade can attract momentum, while RBA/consumer sensitivity is the main counterweight.
What to watch
Lithium impact timing/realization is uncertain (prices up ~60% YTD is cited, but margin sensitivity, offtake terms, and execution risk aren’t quantified in the article).
Background
The piece contrasts WES underperformance versus the ASX 200 and argues the valuation has normalized after trading at ~37x forward earnings in mid-2025.
Ticker impact
Wesfarmers reported a 9.3% NPAT rise for the half-year ended Dec 2025 and Morgans upgraded it to accumulate with an $81.10 target.
Moderate upside bias versus the prior 12-month drawdown, with volatility tied to household spending and RBA expectations.
The article cites specific operating growth (Bunnings/Kmart), higher free cash flow, and a broker upgrade/target, but also flags macro sensitivity and that the stock remains ~28.5x earnings.
Market effects
ASX retail/consumer discretionary sentiment may improve if investors view WES as a quality compounder with improving cash generation.
AU equities could see read-across to other retailers/consumer names if rate-hike fears ease and earnings resilience is emphasized.
Lithium optionality may marginally influence global lithium sentiment, but the article frames it as an earnings contributor rather than a standalone lithium market catalyst.
Counterpoint
Even with lithium turning additive, the stock is still described as not cheap (~28.5x earnings), so multiple compression risk remains if consumer volumes soften.
Key entities
- public_companyWesfarmers Ltd
Reported half-year NPAT of $1,603m (+9.3% YoY), free cash flow +35.6%, and received a Morgans upgrade to accumulate with an $81.10 target.
- brokerMorgans
Upgraded WES to accumulate and cited a valuation re-rating (around 26.5x FY27F PE vs ~37x peak).
- joint_ventureCovalent Lithium (Mt Holland JV with SQM)
Wesfarmers’ 50% stake in the Mt Holland lithium project; the article claims lithium is shifting from cost to contributor as prices rise.
